Mengjin Hu

Dr. Mengjin Hu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
MHMengjin Hu
Mengjin Hu
JTJiang-Shan Tan
Jiang-Shan Tan
XGXiaojin Gao
Xiaojin Gao
JYJingang Yang
Jingang Yang
YYYuejin Yang
Yuejin Yang
Background: A growing number of cohort studies revealed an inverse association between cheese intake and cardiovascular diseases, yet the causal relationship is unclear. Objective: To assess the causal relationship between cheese intake, and cardiovascular diseases and cardiovascular biomarkers. Methods: A two-sample Mendelian randomization (MR) analysis based on publicly available genome-wide association studies was employed to infer the causal relationship. The effect estimates were calculated using the random-effects inverse-variance-weighted method. Results: Cheese intake per standard deviation increase causally reduced the risks of type 2 diabetes (odds ratio (OR) = 0.46; 95% confidence interval (CI), 0.34–0.63; p = 1.02 × 10−6), heart failure (OR = 0.62; 95% CI, 0.49–0.79; p = 0.0001), coronary heart disease (OR = 0.65; 95% CI, 0.53–0.79; p = 2.01 × 10−5), hypertension (OR = 0.67; 95% CI, 0.53–0.84; p = 0.001), and ischemic stroke (OR = 0.76; 95% CI, 0.63–0.91; p = 0.003). Suggestive evidence of an inverse association between cheese intake and peripheral artery disease was also observed. No associations were observed for atrial fibrillation, cardiac death, pulmonary embolism, or transient ischemic attack. The better prognosis associated with cheese intake may be explained by lower body mass index (BMI; effect estimate = −0.58; 95% CI, from −0.88 to −0.27; p = 0.0002), waist circumference (effect estimate = −0.49; 95% CI, from −0.76 to −0.23; p = 0.0003), triglycerides (effect estimate = −0.33; 95% CI, from −0.50 to −0.17; p = 4.91 × 10−5), and fasting glucose (effect estimate = −0.20; 95% CI, from −0.33 to −0.07; p = 0.0003). There was suggestive evidence of a positive association between cheese intake and high-density lipoprotein. No influences were observed for blood pressure or inflammation biomarkers. Conclusions: This two-sample MR analysis found causally inverse associations between cheese intake and type 2 diabetes, heart failure, coronary heart disease, hypertension, and ischemic stroke.

30 August 2022 in Medicina
Verified
Journal Article
Open access
PDF file
MHMengjin Hu
Mengjin Hu
SHSong Hu
Song Hu
XGXiaojin Gao
Xiaojin Gao
YYYuejin Yang
Yuejin Yang
Background and objectives: The effect of beta-blocker use after discharge on patients with acute myocardial infarction (AMI) in the contemporary reperfusion era remains ambiguous. By applying meta-analysis, we sought to assess the role of beta-blockers in the contemporary reperfusion era. Materials and Methods: Randomized controlled trials (RCT) and observational studies using propensity score matching, comparing use of beta-blockers with non-use of beta-blockers, in patients with AMI after discharge. The primary outcome was all-cause mortality. Odds ratios (OR) and associated 95% confidence intervals (CI) were calculated. Results: One RCT and eight observational studies, containing 47,339 patients with AMI, were included. Compared with non-use of beta-blockers, beta-blocker use after discharge may have reduced the risk of all-cause mortality (OR: 0.70, 95% CI: 0.61 to 0.80, I2 = 14.4%), cardiac death (OR: 0.63, 95% CI: 0.44 to 0.91, I2 = 22.8%), myocardial infarction (OR: 0.73, 95% CI: 0.62 to 0.86, I2 = 0), and revascularization (OR: 0.92, 95% CI: 0.85 to 0.99, I2 = 0). No significant differences were found in major adverse cardiovascular events (MACE, OR: 0.88, 95% CI: 0.66 to 1.17, I2 = 78.4%), heart failure (OR: 0.56, 95% CI: 0.29 to 1.08, I2 = 0) or stroke (OR: 1.13, 95% CI: 0.92 to 1.39, I2 = 0). For patients with preserved left ventricular function, beta-blocker use after discharge may have also reduced the risk of all-cause mortality (OR: 0.61, 95% CI: 0.44 to 0.84, I2 = 0). Conclusions: Use of beta-blockers after discharge may still be beneficial for AMI patients in the contemporary reperfusion era, with or without preserved left ventricular function.

Verified
Journal Article
Open access
PDF file
MHMengjin Hu
Mengjin Hu
XWXiaoning Wang
Xiaoning Wang
JTJiang-Shan Tan
Jiang-Shan Tan
JYJingang Yang
Jingang Yang
XGXiaojin Gao
Xiaojin Gao
YYYuejin Yang
Yuejin Yang
Background: Observational studies have suggested that paternal longevity is associated with reduced risks of cardiovascular diseases, yet the causal association remains to be determined. Objectives: To investigate whether Mendelian randomization (MR) results support a causal role of paternal longevity for risks of cardiovascular diseases. Methods: Genetic variants associated with paternal longevity and cardiovascular diseases were obtained from public genome-wide association study data. We used inverse variance weighted MR under a random-effects model to provide causal estimates between paternal longevity and cardiovascular diseases. Results: Paternal longevity was associated with decreased risks of coronary heart disease (odds ratio (OR): 0.08; 95% confidence interval (CI): 0.02–0.37; p = 0.001) and peripheral artery disease (OR: 0.15; 95% CI: 0.03–0.65; p = 0.011). No significant differences were observed in hypertension, atrial fibrillation, heart failure, transient ischemic attack, ischemic stroke, or cardiac death. The weighted median method revealed consistent results between genetically instrumented paternal longevity and decreased risk of coronary heart disease and peripheral artery disease. No significant differences were observed in the MR-Egger results. Multivariable MR consistently indicated causal associations between paternal longevity and decreased cardiovascular diseases. The leave-one-out analysis suggested that the causal associations were not affected by individual single-nucleotide polymorphisms. The intercept of the MR-Egger estimator and funnel plot revealed no indication of horizontal pleiotropic effects. Conclusions: Our MR analyses supported a causal role of paternal longevity for decreased risks of coronary heart disease and peripheral artery disease, which highlighted the need for better monitoring and intervention of cardiovascular diseases in populations with premature paternal death.

Verified
Journal Article
Open access
PDF file
MHMengjin Hu
Mengjin Hu
XGXiaojin Gao
Xiaojin Gao
JYJingang Yang
Jingang Yang
YYYuejin Yang
Yuejin Yang
Objective: To test the optimal strategy of dual antiplatelet therapy (DAPT) after implantation of drug-eluting stents (DESs) according to specific DAPT time and subsequent monotherapy. Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, and Web of Science to identify randomized controlled trials (RCTs). Six DAPT strategies were compared: 1-month DAPT followed by P2Y12 inhibitor monotherapy, 3-month DAPT followed by P2Y12 inhibitor monotherapy, 3-month DAPT followed by aspirin monotherapy, 6-month DAPT followed by aspirin monotherapy, 12-month DAPT, and >12-month DAPT. Pooled odd ratios (ORs) with 95% credible intervals (CrIs) were calculated to summarize the effect of each strategy tested. Results: We identified 24 RCTs containing 81,405 patients. In comparison with 12-month DAPT, 3-month DAPT followed by P2Y12 inhibitor monotherapy reduced net clinical events (OR: 0.72; CrI: 0.55–0.94). Major bleeding (OR: 0.57; CrI: 0.34–1.00) was marginally decreased without impact on ischemic events (OR: 0.93; CrI: 0.68–1.29). Moreover, the benefits of 3-month DAPT (P2Y12 inhibitor) were consistent for male patients with acute coronary disease, young age, complex lesion, single-vessel disease, low body mass index, and without diabetes. Although >12-month DAPT was associated with a lower risk of myocardial infarction (OR: 0.67; CrI: 0.51–0.93), the risk of major bleeding (OR: 1.70; CrI: 1.10–2.70) was increased. Conclusion: Among patients treated with DESs, 3-month DAPT followed by P2Y12 inhibitor monotherapy may be the optimal antiplatelet strategy, while DAPT beyond 1 year reduces myocardial infarction at the expense of increased major bleeding.

3 August 2026 in Biopsychosocial Science and Medicine
Verified
Journal Article
Open access
FSFei Song
Fei Song
MHMengjin Hu
Mengjin Hu
JXJinggang Xia
Jinggang Xia
CYChunlin Yin
Chunlin Yin
Objective: To examine the association between body roundness index (BRI) and cardio-metabolic-depression multimorbidity. Methods: This study used data of two prospective cohorts: China Health and Retirement Longitudinal Study (CHARLS) and English Longitudinal Study of Ageing (ELSA). Firstly, the relationship between baseline BRI and the incidence of cardio-metabolic-depression multimorbidity was analyzed using Cox regression models. Subsequently, stratified Cox models with interaction terms were conducted among different groups. To investigate the potential nonlinear relationships, restricted cubic spline (RCS) regression of hazard ratio (HR) was employed. Furthermore, longitudinal associations between BRI and cardio-metabolic-depression multimorbidity over time were estimated by using generalized estimating equations (GEE) model. Results: A total of 12,840 participants from CHARLS (female: 52.7%, mean age: 58.39 y), 6962 from ELSA (female: 55.0%, mean age: 65.94 y) were included according to inclusion and exclusion criteria. Cox models revealed consistent and significant association between BRI (continuous and quartiles) and cardio-metabolic-depression multimorbidity risk. Fully adjusted HRs showed a progressive increase compared to Q1, indicating a strong graded association ( P for trend <0.001). Stratified analyses showed no significant interactions by demographic and lifestyle factors. In both cohorts, RCS analyses revealed particularly steep risk gradients beyond BRI values of 4. GEE analyses confirmed significant longitudinal associations with cardio-metabolic-depression multimorbidity risk. Sensitivity analyses including landmark, outlier exclusion, and multiple imputation approach consistently supported these findings. Conclusions: Higher BRI consistently predicts cardio-metabolic-depression multimorbidity across populations in a dose-dependent patterns. These findings highlight BRI’s potential for early risk stratification and integrated care approaches that target metabolic-mental health interactions.